| Nov 13 |
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
|
| Nov 8 |
Design Therapeutics GAAP EPS of -$0.23 beats by $0.02
|
| Nov 7 |
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
|
| Nov 6 |
We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely
|
| Sep 26 |
Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock
|
| Sep 10 |
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
|
| Aug 21 |
Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet
|
| Aug 16 |
With 34% ownership, Design Therapeutics, Inc. (NASDAQ:DSGN) has piqued the interest of institutional investors
|
| Aug 5 |
Design Therapeutics GAAP EPS of -$0.21
|
| Aug 5 |
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio
|
